niphon/iStock via Getty Images
- Immunovant (IMVT) rose 14% amid some takeover speculation.
- There’s speculation that Immunovant has attracted takeover interest, according to traders, who cited a Betaville “uncooked” alert that was circulating on Thursday. One of the companies interested in buying Immunovant is Roivant (ROIV), Immunovant’s largest shareholder.
- Immunovant (IMVT) has a market cap of $3.8 billion.
- Immunovant (IMVT) is set to report its Q3 results on Nov. 10.